Project: Trafficking of botulinum toxins in enteric nervous system / Prijenos botulinum toksina u enteričkom živčanom sustavu
Project leader: Ivica Matak, PhD, Research associate
Project collaborators: assist. prof. Ornella Rossetto, PhD; Marco Pirazzini, PhD, Research associate; Federico Fabris, M.Biotechnol / PhD candidate
Project duration: 01/10/2019 – 01/12/2019
This project is supported by Unity Through Knowledge Fund (UKF) Project call: “Gaining experience (2019), and the research group of assist. prof. Ornella Rossetto, Department of Biomedical Sciences, University of Padua, Italy


The aim of project visit is to establish collaboration and to share experimental experience between the visitor (Ivica Matak, Laboratory of Molecular Neuropharmacology, Department of Pharmacology, University of Zagreb School of Medicine), and the Neuroparalysis and Neuroregeneration Lab, at the Department of Biomedical Sciences at the University of Padua. Ivica Matak’s visit, lasting for two months, will be supervised by prof. Ornella Rossetto, one of the pioneering scientists in the investigation of basic mechanisms of action of botulinum toxin type A (BoNT/A) and other clostridial neurotoxins which characterized toxin entrance into neurons and translocation into neuronal cytosol and action on synaptic proteins, and characterization of the effects on the neuromuscular junction (Pirrazzini et al., 2017; Pirazzini et a., 2014; Schiavo et al., 1992).
During the proposed visit, Ivica Matak will join the ongoing research of the group in Padua involving investigation of botulinum toxins’ action on enteric nervous system. Different immunological serotypes of botulinum toxins, produced by anaerobic bacterium Clostridium botulinum are the most potent toxins known (Matak and Lacković, 2014; Pirazzini et al., 2017). The most common pathway of intoxication is ingestion of Clostridium-intoxicated food prepared in anaerobic conditions, and toxin absorption into the bloodstream through the intestinal gut lining (Arnon et al., 2001; Maxymowich et al, 1999)

Figure 1 Pharmacokinetics of botulinum neurotoxin type A (BoNT/A). Ingested or inhaled BoNT/A complex reaches the lumen of intestines or lung alveoles, and the neurotoxic part enters the bloodstream by transcytosis across epithelial layers. This is followed by systemic distribution into the extracellular fluid of peripheral tissues, such as muscles (auxiliary proteins indicated by dashed circle line dissociate from 150 kDa neurotoxin). Systemically distributed or intramuscularly (i.m.) injected BoNT/A then enters neuromuscular junctions and paralyses the muscle. Circulating BoNT/A cannot penetrate the blood-brain barrier, however, a portion of BoNT/A is retrogradely transported within peripheral nerves towards the CNS. Favorable pharmacokinetic properties for high BoNT/A toxicity are: the ability to survive the harsh conditions of GI tract and cross the epithelial layers to reach the bloodstream, sufficient half-life in the systemic bloodstream and specific recognition of neuronal terminals to promptly enter the cytosol of neuronal terminals (Ivica Matak, PhD thesis 2015).
The relevance of research theme is supported by clinical experience in botulism intoxication, as well as off label therapeutic use in treatment of gastrointestinal disorders (Brisinda et al., 2015; Vittal et al., 2006). Present knowledge suggests that botulinum toxins possess the effect in the enteric nervous system. However, most aspects of the botulinum toxin action, such as cell types targeted, distribution to distant body regions from the gut, possible interaction with the resident local immune system cells, as well as toxin distribution into CNS after toxin distribution from the gut, have never been characterized (Rossetto et al., 2015). It is of particular interest to study these actions since they are pathophysiologically relevant for the management of botulism, as well as potential therapeutic implications for the treatment of gastrointestinal disorders along different part of the gut axis, such as dysphagia, achalasia, dyspepsia, different intestinal hypermotility disorders, inflammatory bowel disorders, sphincter disorders etc.
The costs of travel, accommodation and monthly allowance are covered by Unity Through knowledge Fund (UKF), while the costs of research are covered by the Ornella Rossetto group, University of Padua. Total amount of funds = 24.500,00 HRK (Unity Through Knowledge Fund 20.000,00 HRK, University of Padua 4.500,00 HRK)
Objectives, significance and added value of the visit
Expected measurable results of the visit and their potential users
Relevance and potential benefit of the visit
Plans for future collaborations, project applications and publications with host organization or other scientific groups in the world or private sector
Proposed communication and outreach of results
Management and organization of the visit
Literature references
Results of the projects